

**GAD1 Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP11228b****Specification**

---

**GAD1 Antibody (C-term) Blocking peptide - Product Information**Primary Accession [Q99259](#)**GAD1 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 2571**Other Names**

Glutamate decarboxylase 1, 67 kDa glutamic acid decarboxylase, GAD-67, Glutamate decarboxylase 67 kDa isoform, GAD1, GAD, GAD67

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**GAD1 Antibody (C-term) Blocking peptide - Protein Information****Name** GAD1 ([HGNC:4092](#))**Synonyms** GAD, GAD67**Function**

Catalyzes the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) with pyridoxal 5'-phosphate as cofactor.

**Tissue Location**

[Isoform 1]: Expressed in brain.

**GAD1 Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**GAD1 Antibody (C-term) Blocking peptide - Images**

**GAD1 Antibody (C-term) Blocking peptide - Background**

This gene encodes one of several forms of glutamic acid decarboxylase, identified as a major autoantigen in insulin-dependent diabetes. The enzyme encoded is responsible for catalyzing the production of gamma-aminobutyric acid from L-glutamic acid. A pathogenic role for this enzyme has been identified in the human pancreas since it has been identified as an autoantigen and an autoreactive T cell target in insulin-dependent diabetes. This gene may also play a role in the stiff man syndrome. Deficiency in this enzyme has been shown to lead to pyridoxine dependency with seizures. Alternative splicing of this gene results in two products, the predominant 67-kD form and a less-frequent 25-kD form.

**GAD1 Antibody (C-term) Blocking peptide - References**

Lanoue, A.C., et al. Exp. Neurol. 226(1):207-217(2010) Jia, P., et al. Schizophr. Res. 122 (1-3), 38-42 (2010) : Terranova, C., et al. Alcohol 44(5):407-413(2010) Ruano, G., et al. Pharmacogenomics 11(7):959-971(2010) Jugessur, A., et al. PLoS ONE 5 (7), E11493 (2010) :